NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine. Noom will offer its version of compounded semaglutide - the active ingredient in Wegovy and diabetes drug Ozempic - as part of a program personalized for patients, which it says will comply with changing U.S. Food and Drug Administration regulations. Demand for the new generation of highly effective but pricey weight-loss drugs has catapulted sales at Noom and rival telehealth sites including Hims & Hers, WeightWatchers and Ro over the past two years.